301267 华厦眼科
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,050,5012.85%4,013,1643,233,2463,064,4372,514,668
减:营业总成本1,690,20312.09%3,144,2142,538,4352,451,1472,087,633
    其中:营业成本1,110,54512.08%2,045,4241,679,7251,653,6301,454,475
               财务费用14,83061.90%20,00831,69640,2678,832
               资产减值损失(1,030)7,685.17%(5,552)(727)(713)(424)
公允价值变动收益22,414162.53%11,0216,512----
投资收益12,429-60.19%76,4387,9938,7342,314
    其中:对联营企业和合营企业的投资收益------------
营业利润407,935-21.87%973,397727,448651,730484,411
利润总额356,816-23.44%854,313653,613582,333459,743
减:所得税费用83,448-17.28%176,893144,415128,702138,292
净利润273,367-25.14%677,420509,199453,631321,452
减:非控股权益7,871-24.92%11,488(4,623)(1,288)(13,012)
股东净利润265,496-25.15%665,932513,821454,919334,464

市场价值指针
每股收益 (元) *0.320-23.81%0.7900.6700.9100.670
每股派息 (元) *----0.1100.280----
每股净资产 (元) *6.729-28.99%6.7329.1323.6602.840
审计意见 #--标准的无保留意见标准的无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容